The FDA has given its approval to Toviaz as a cure for overactive bladders in adult patients. The drug is manufactured by Schwarz Pharma of Zwickau, Germany, and is distributed in the United States by Pfizer Inc. (NYSE:PFE) of New York. FDA has given approval for two doses of the drug – 4mg and 8 mg.

Toviaz (fesoterodine fumarate) relaxes the smooth muscle tissue of the bladder. Thus it reduces urinary frequency, the urge to urinate and sudden urinary involuntary urination. All these symptoms indicate an active bladder.

"Patients who suffer from overactive bladder face quality of life issues that can hamper their ability to enjoy life to its fullest," said Dr. George Benson, deputy director of the Division of Reproductive and Urologic Products at the FDA's Center for Drug Evaluation and Research. "This new drug will provide an additional treatment option to help them manage problems with an overactive bladder."